SNSS


Stock Update (NASDAQ:SNSS): Sunesis Pharmaceuticals, Inc. Announces Presentation of Results from Completed Phase 1A Healthy Volunteer Study at ASH Annual Meeting

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced the presentation of results from the Company’s Phase 1A study in healthy volunteers evaluating oral non-covalent reversible BTK …

Stock Update (NASDAQ:SNSS): Sunesis Pharmaceuticals, Inc. Announces Pricing of $25 Million Offering of Securities

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced the pricing of underwritten offerings of (i) 4,935,500 shares of its common stock at a price of $3.

Company Update (NASDAQ:SNSS): Sunesis Pharmaceuticals, Inc. Announces Submission of Responses to the EMA Day 120 List of Questions for Marketing Authorization Application for Vosaroxin

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced that it has submitted its responses to European Medicines Agency (EMA) Day 120 List of Questions issued by the …

Company Update (NASDAQ:SNSS): Sunesis Pharmaceuticals, Inc. Announces 1-for-6 Reverse Stock Split

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a …

Cowen Comments on Sunesis Pharmaceuticals, Inc. (SNSS) Following 2Q:16 Update

Cowen analyst Eric Schmidt weighed in today with a few insights on Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), after the company reported second-quarter financials and provided investors …

Monday Morning’s Market Insights: LinkedIn Corp (LNKD), Eleven Biotherapeutics Inc (EBIO), MannKind Corporation (MNKD), Sunesis Pharmaceuticals, Inc. (SNSS)

LinkedIn Corp (NYSE:LNKD) is up a whopping 48% after Microsoft agreed to buy the company for $26.2 billion in cash.

Company Update (NASDAQ:SNSS): Sunesis Pharmaceuticals, Inc. Announces Presentation of Positive Clinical Results in Frontline Elderly AML and MDS at the EHA Annual Meeting

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced the presentation of updated results from an ongoing Phase 1b/2University of Texas MD Anderson Cancer Center-sponsored trial of vosaroxin …

Stock Update (NASDAQ:SNSS): Sunesis Pharmaceuticals, Inc. Appoints Linda Neuman, M.D., as Vice President, Clinical Development

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced that Linda Neuman, M.

Company Update (NASDAQ:SNSS): Sunesis Pharmaceuticals, Inc. Announces Support of First-Ever Acute Myeloid Leukemia Awareness Month in June

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced its support for the first-ever Acute Myeloid Leukemia Awareness Month to be held in June.

Company Update (NASDAQ:SNSS): Sunesis Pharmaceuticals, Inc. Reports Fourth Quarter and Full-Year 2015 Financial Results and Recent Highlights

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) reported financial results for the fourth quarter and year ended December 31, 2015.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts